Day One Biopharmaceuticals Gelecekteki Büyüme
Future kriter kontrolleri 5/6
Day One Biopharmaceuticals is forecast to grow earnings and revenue by 66.8% and 39.4% per annum respectively. EPS is expected to grow by 65.4% per annum. Return on equity is forecast to be -41% in 3 years.
Anahtar bilgiler
66.8%
Kazanç büyüme oranı
65.4%
EPS büyüme oranı
| Biotechs kazanç büyümesi | 27.1% |
| Gelir büyüme oranı | 39.4% |
| Gelecekteki özkaynak getirisi | -41.0% |
| Analist kapsamı | Good |
| Son güncelleme | 01 Nov 2024 |
Gelecekteki son büyüme güncellemeleri
Recent updates
We Think Day One Biopharmaceuticals (NASDAQ:DAWN) Can Afford To Drive Business Growth
Jul 12
Day One Biopharmaceuticals: Still Uncertainty After FDA Approval
Jul 07Day One Pharmaceuticals: Ojemda Approval A Big Win, Current Valuation Fair
Apr 24We're Hopeful That Day One Biopharmaceuticals (NASDAQ:DAWN) Will Use Its Cash Wisely
Mar 18Navigating Day One Biopharmaceuticals' Financial Health And Clinical Prospects
Feb 01We're Hopeful That Day One Biopharmaceuticals (NASDAQ:DAWN) Will Use Its Cash Wisely
Dec 04We're Not Very Worried About Day One Biopharmaceuticals' (NASDAQ:DAWN) Cash Burn Rate
Jun 19We're Hopeful That Day One Biopharmaceuticals (NASDAQ:DAWN) Will Use Its Cash Wisely
Mar 08Here's Why We're Not Too Worried About Day One Biopharmaceuticals' (NASDAQ:DAWN) Cash Burn Situation
Nov 22Day One Biopharmaceuticals: Recent Strong Data, And Major Catalysts Ahead
Sep 04Day One Biopharmaceuticals GAAP EPS of -$0.60
Aug 04Day One Biopharmaceuticals, Inc.'s (NASDAQ:DAWN) Intrinsic Value Is Potentially 52% Above Its Share Price
Jun 18Day One Biopharmaceuticals: Early Pediatric Brain Cancer Data Makes Tentative Buy Case
Jun 15We're Not Very Worried About Day One Biopharmaceuticals' (NASDAQ:DAWN) Cash Burn Rate
Apr 29An Intrinsic Calculation For Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Suggests It's 42% Undervalued
Jan 14Day One Biopharmaceuticals (NASDAQ:DAWN) Is In A Good Position To Deliver On Growth Plans
Dec 10Day One Biopharmaceuticals (NASDAQ:DAWN) Is In A Good Position To Deliver On Growth Plans
Aug 27Day One Biopharma draws bullish calls as quiet period ends
Jun 21Kazanç ve Gelir Büyüme Tahminleri
| Tarih | Gelir | Kazançlar | Serbest Nakit Akışı | Faaliyetlerden Nakit | Avg. Analist Sayısı |
|---|---|---|---|---|---|
| 12/31/2026 | 301 | -12 | 45 | -9 | 9 |
| 12/31/2025 | 162 | -109 | -117 | -138 | 10 |
| 12/31/2024 | 112 | -85 | -210 | -28 | 10 |
| 9/30/2024 | 102 | -84 | -162 | -89 | N/A |
| 6/30/2024 | 8 | -167 | -197 | -177 | N/A |
| 3/31/2024 | N/A | -209 | -174 | -171 | N/A |
| 12/31/2023 | N/A | -189 | -150 | -147 | N/A |
| 9/30/2023 | N/A | -175 | -144 | -141 | N/A |
| 6/30/2023 | N/A | -166 | -127 | -127 | N/A |
| 3/31/2023 | N/A | -157 | -114 | -114 | N/A |
| 12/31/2022 | N/A | -142 | -110 | -110 | N/A |
| 9/30/2022 | N/A | -124 | -88 | -88 | N/A |
| 6/30/2022 | N/A | -105 | -77 | -77 | N/A |
| 3/31/2022 | N/A | -183 | -60 | -60 | N/A |
| 12/31/2021 | N/A | -171 | -57 | -49 | N/A |
| 9/30/2021 | N/A | -183 | -49 | -41 | N/A |
| 6/30/2021 | N/A | -167 | -41 | -33 | N/A |
| 3/31/2021 | N/A | -54 | -29 | -21 | N/A |
| 12/31/2020 | N/A | -41 | -14 | -13 | N/A |
Analist Gelecek Büyüme Tahminleri
Kazançlar ve Tasarruf Oranları: DAWN is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.5%).
Kazançlar ve Piyasa: DAWN is forecast to become profitable over the next 3 years, which is considered above average market growth.
Yüksek Büyüme Kazançları: DAWN is expected to become profitable in the next 3 years.
Gelir ve Pazar: DAWN's revenue (39.4% per year) is forecast to grow faster than the US market (8.9% per year).
Yüksek Büyüme Geliri: DAWN's revenue (39.4% per year) is forecast to grow faster than 20% per year.
Hisse Başına Kazanç Büyüme Tahminleri
Gelecekteki Özkaynak Getirisi
Gelecekteki ROE: DAWN is forecast to be unprofitable in 3 years.